Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Swollen lymph nodes serve as a crucial early warning system when the body fights HIV. These changes often appear subtle at first but persist beyond the duration of typical viral infections.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Incidence assays for differentiating early from established HIV infection To understand the epidemiology of HIV, the incidence of infection must be estimated. Immunoassays for assessing prevalence ...

Older adults with HIV are at significantly higher risk for cutaneous malignancies when compared with younger patients with HIV.